Patent · US Active

Overexpression of FOXC1 to treat corneal vascularization

US11001618B2 · kind B2 · utility

0Cited by

5References

3Claims

0Family size

Assignees

Northwestern University · US
The Governors of the University of Alberta · CA

Inventors

Tsutomu Kume · Ibaraki, JP
Ordan Lehmann · Edmonton, CA

Key dates

Filing date	Feb 18, 2019
Grant date	May 11, 2021
Priority date	—
Expiry date	Mar 30, 2039

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2750/14143
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Disclosed are methods and pharmaceutical compositions for treating and inhibiting conical vascularization including conical vascularization associated with viral infection, chemical injury, autoimmune conditions, and post-corneal transplantation or in subjects having a PAX6 mutation associated with conical vascularization. The methods and pharmaceutical compositions are utilized in administering treatment that results in increased concentration of FOXC1 in a subject's cornea in order to treat or inhibit corneal vascularization.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.